Clinical trials
HSCT clinical trials
Below are recruiting hsct clinical trials, each written for real people, not researchers. We’re tracking 160 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06232694Recruiting
Combination therapy for newly diagnosed AML
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
Nanjing, JiangsuAges 18–60 - NCT06211166Recruiting
Tracking cancer genes after stem cell transplant with digital PCR
This trial uses a precise blood test called digital PCR to measure tiny amounts of leftover cancer cells in patients who have had a stem cell transplant. It helps doctors see how well the transplant is working and if more treatment is needed.
Beijing, Beijing MunicipalityAges Any age - NCT06199427RecruitingPhase 2
Preventing graft-versus-host disease after stem cell transplant for immune disorders
This trial tests a combination of two drugs, ruxolitinib and PTCy, to prevent graft-versus-host disease (a common complication) in children receiving a stem cell transplant for inborn errors of immunity. The goal is to make the transplant safer and more effective.
MoscowAges birth–21 years - NCT06198842RecruitingPhase 2
Low-dose treosulfan with PTCy for Nijmegen Breakage Syndrome transplant
This trial tests a low-dose chemotherapy regimen (treosulfan) combined with a drug called PTCy to prepare children with Nijmegen Breakage Syndrome for a stem cell transplant. The goal is to reduce side effects while helping the donor cells take hold safely.
MoscowAges 3 months–21 years - NCT06130579RecruitingPhase 2
Interferon-α for TP53-mutated blood cancer after transplant
This trial tests whether a medicine called interferon-α can help people with a specific gene mutation (TP53) in their blood cancer after they've had a donor stem cell transplant. It aims to prevent the cancer from coming back.
Beijing, Beijing MunicipalityAges 12–65 - NCT06155188Recruiting
New transplant method for childhood leukemia
This study tests a new combination of medicines to help donor cord blood cells grow better in children with leukemia after a transplant.
Guangzhou, GuangdongAges 1 month–18 years - NCT06125483Recruiting
Cord blood transplant for cancer relapse after stem cell transplant
This trial tests a second transplant using cord blood after a first stem cell transplant failed to keep the cancer away. It's for people with blood cancers like leukemia that have come back.
Suzhou, JiangsuAges 10–65 - NCT06111612Recruiting
Intensive chemo before stem cell transplant for myeloid cancers with spread outside marrow
This trial tests a stronger chemotherapy combination before a donor stem cell transplant for people with certain blood cancers (like AML, MDS, or CMML) that have spread to other parts of the body, such as the skin, testicles, or central nervous system. The goal is to see if this approach can improve outcomes for patients whose disease is in remission.
Shanghai, Shanghai MunicipalityAges 18–55 - NCT06093867Recruiting
Tracking lung health after stem cell transplant
This study follows people getting a stem cell transplant to watch for lung problems, like infections or other lung diseases, that can happen after the transplant. The goal is to catch these issues early.
Bethesda, MarylandAges 5–70 - NCT06082947Recruiting
Stem cell transplant with special cell depletion for children and young adults
This trial tests a type of stem cell transplant that removes certain immune cells (alpha-beta T cells and CD19 B cells) from the donor cells. This may help prevent graft-versus-host disease and other complications in patients with blood cancers who do not have a matched sibling donor.
Columbus, OhioAges Up to 30 years - NCT06071637RecruitingPhase 3
Preventing mouth sores with laser therapy in stem cell transplant
This trial tests if a low-power laser can prevent painful mouth sores and throat pain in people getting a stem cell transplant from a donor. The laser is applied to the mouth before sores start, aiming to reduce pain and speed healing.
Rio de Janeiro, Rio de JaneiroAges 18–100 - NCT05805605RecruitingPhase 2
Low-intensity stem cell transplant with donor cells and blood-protection
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
Minneapolis, MinnesotaAges Up to 75 years - NCT07586735Recruiting
A new preparative regimen for stem cell transplant in older patients with severe aplastic anemia
This study tests a new combination of drugs to prepare older patients (40–60 years old) with severe aplastic anemia for a stem cell transplant from a half-matched donor. The goal is to make the transplant safer and more effective for this age group.
Beijing, Beijing MunicipalityAges 40–60 - NCT05940961RecruitingPhase 2
Inotuzumab for MRD-positive B-cell leukemia after transplant
This trial studies inotuzumab, a targeted cancer drug, for people whose B-cell ALL has returned at a very low level after a bone-marrow or stem-cell transplant. If you qualify, it may help push the leukemia back under control after transplant.
Suzhou, JiangsuAges 15–65 - NCT05902416Recruiting
Testing haplo transplant for older adults with leukemia or MDS
This study looks at using a “half-matched” stem cell transplant (haploidentical transplant) in adults around your age with acute leukemia or MDS. It may help people who cannot find a fully matched donor, but are still eligible for this type of transplant.
Beijing, Beijing MunicipalityAges 55–70 - NCT05797272Recruiting
In-utero stem cell treatment for Bart’s hydrops
This trial studies whether giving hematopoietic (blood-forming) stem cells while the baby is still in the womb can treat fetuses with Bart’s hydrops fetalis syndrome. It aims to improve outcomes after prenatal intervention in carefully selected pregnancies.
ShatinAges 18 years+ - NCT05788679RecruitingPhase 2
Use a patient’s genetic test to guide treatment after transplant
This study looks at a personalized lab test to detect small amounts of disease after a stem cell transplant and then decide what treatment comes next. It may help some people with certain bone-marrow diseases stay in remission while avoiding unnecessary treatment.
StockholmAges 18 years+ - NCT03810196Recruiting
Stem cell addback after transplant to treat viral or fungal infection
This study tests a stem cell “addback” treatment after a specific type of transplant (with certain immune cells removed). It may help the body recover faster and fight serious viral or fungal infections in children and teens.
Philadelphia, PennsylvaniaAges Up to 25 years - NCT05772273Recruiting
Test PD-1 drug plus azacitidine and donor cells for AML relapse
This study tests whether combining a PD-1 immune therapy, azacitidine, and low-dose donor lymphocyte infusion (donor immune cells) can treat AML that has come back after a stem cell transplant. It may help some people regain anti-cancer immune activity after relapse.
Suzhou, JiangsuAges Any age - NCT07689630RecruitingPhase 3
Antibody to prevent GVHD in half-matched stem cell transplant
This study is testing whether giving a special antibody (anti-CD25) before a half-matched stem cell transplant can prevent a common side effect called graft-versus-host disease (GVHD), where donor cells attack your body. It is for people with blood cancers who are getting this type of transplant.
Wuhan, HubeiAges 18–75 - NCT05682755RecruitingPhase 1/Phase 2
Chidamide to Prevent AML Return After Bone Marrow Transplant
This Phase 1/2 study tests whether chidamide can help prevent high-risk acute myeloid leukemia (AML) from coming back after an allogeneic bone marrow transplant (allo-HSCT). Participants must already be in complete remission and have recovered blood counts after transplant.
Chengdu, SichuanAges 18–65 - NCT05027945RecruitingPhase 2
Stem cell transplant for people with VEXAS syndrome
This Phase 2 trial tests whether an allogeneic stem cell transplant (from a donor) can treat VEXAS syndrome. It may help calm the body’s overactive inflammation and improve symptoms in eligible adults.
Bethesda, MarylandAges 18–75 - NCT05531786RecruitingPhase 1/Phase 2
Pacritinib for hard-to-treat chronic graft-versus-host disease
This early-phase study tests pacritinib, a targeted medicine, for chronic graft-versus-host disease (cGVHD) that hasn’t improved after prior treatments. If you qualify, the goal is to reduce cGVHD symptoms and improve how well you function after a stem cell transplant.
Miami, FloridaAges 18–120 - NCT05436418RecruitingPhase 1/Phase 2
Lower-dose transplant medicines to prevent graft-versus-host disease
This early-phase study tests a lower dose of cyclophosphamide given after a stem cell transplant to prevent graft-versus-host disease (GVHD). It also uses sirolimus and mycophenolate to improve how well the donor immune system accepts the transplant, aiming to reduce side effects while keeping protection against GVHD.
Duarte, CaliforniaAges 12–120
Hear when a new HSCT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hsct?
- Yes. Clin2 currently lists 160 recruiting hsct studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hsct trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hsct trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.